Development of a near infrared region based non-invasive therapy device for diabetic peripheral neuropathy

Sci Rep. 2024 Nov 14;14(1):27993. doi: 10.1038/s41598-024-78144-5.

Abstract

Diabetic Peripheral Neuropathy (DPN) is a nerve damage that is treated with painkillers and steroids which have the drawback of interference with other medications and the dangers of side effects. Novelty of the proposed work is to develop a Near Infrared Region (NIR) based non-invasive therapy device called 'DPNrelief-1.0V'developed with a 890 nm wavelength diodes. DPNrelief-1.0V delivers a total dosage of 6.174 J/cm2 with heat absorption by tissue of 61.74 Joules at 30 minutes. The device was tested by carrying out a pilot study with 8 patients where 4 were treatment group and control group. The DPNrelief-1.0V is validated by Nerve Conduction Study (NCS) test. The degenerated nerves pre-therapy showed less amplitude, Conduction Velocity (CV) and latency which was improved post-therapy by 100% in amplitude of nerve signal, 100% in CV and a decrease of 36.2% in latency. Independent t-test was conducted to find the difference between control and treatment, wherein a p value < 0.05 was obtained depicting significant difference between two groups. Furthermore, the performance of the device is validated by one-way test repeated measures Analysis of Variance (ANOVA), wherein a p value of < 0.05 was obtained depicting a difference in nerve condition pre-and post-therapy. The performance of DPNrelief-1.0V has outperformed Anodyne therapy device with lesser dosage, treatment time and portability and in curing the symptoms of DPN. DPNrelief-1.0V finds its potential in the field of medicine for treating DPN.

Keywords: Diabetic peripheral neuropathy; Hardware design; Near infrared spectroscopy therapy; Nerve conduction study; Therapy device.

MeSH terms

  • Adult
  • Aged
  • Diabetic Neuropathies* / therapy
  • Female
  • Humans
  • Infrared Rays* / therapeutic use
  • Male
  • Middle Aged
  • Neural Conduction
  • Pilot Projects